NextGen Medicine basket and the protein folding problem NextGen Medicine basket and the protein folding problem NextGen Medicine basket and the protein folding problem

NextGen Medicine basket and the protein folding problem

Peter Garnry

Head of Equity Strategy

Summary:  DeepMind's AlphaFold algorithm for predicting the 3D shape of protein folding is one of the biggest scientific breakthroughs in biology the last 50 years and solves a long standing problem. The breakthrough will likely lead to the Nobel Prize in chemistry and advance drug discovery on a scale we could only dream of a decade ago. AlphaFold underpin why our NextGen Medicine basket is such an important theme for investors to be exposed to long-term as biotechnology companies could end up being the big winners over the next couple of decades.

DeepMind’s gift to humanity will unleash massive innovation in medicine

In the midst of a global pandemic the world experienced two major breakthroughs in medicine and biochemistry in November 2020. First, Pfizer with its partner BioNTech announced a highly effective vaccine against Covid-19 using mRNA technology for the first time ever in history; it became the fastest developed vaccine in the world. Later during the month Nature announced a ground-breaking scientific discovery from Google’s AI unit DeepMind in which the company’s deep learning algorithm called AlphaFold is able to predict the 3D shape of proteins. Scientists agreed that “It will change everything” and DeepMind chose to make their AlphaFold Protein Structure Database available for free to all scientists.

Around 20 months later DeepMind went a step further announcing that it has, in collaboration with the European Bioinformatics Institute, catalogued nearly all protein known in the universe expanding the database of protein structures from 1 to 200 million structures. Before AlphaFold experimental work had unveiled around 190,000 protein structures. This new database gifted to humanity will advance our understanding of biology and potentially lead to quantum leaps in drug discovery. DeepMind’s scientific breakthrough solves the 50-year problem of protein folding and will most likely lead to the Nobel Prize in Chemistry.

Investors must have exposure to “biology” in their long-term portfolios

The 21st century has often been labelled the century of biology in which computational biology and breakthroughs such as AlphaFold will deliver better and faster drugs to combat diseases. Our NextGen Medicine basket consists of 30 companies representing the long tail of innovation inside the biotechnology industry which today is dominated by a group of very large and successful companies such Amgen, Gilead Sciences, and Vertex Pharmaceuticals etc. Our focus has been on some of the newer technologies within biotechnology such as mRNA, gene therapy, gene editing etc.

The world’s leading biotechnology index which tracks the largest and most liquid biotechnology companies is called NASDAQ Biotechnology Index and it has returned 9.7% annualised since late 2003 compared to 8.1% for MSCI World Index generating 1.6% annualised alpha. The amount of alpha has shrunk considerably the past year as rising interest rates has pushed down equity valuations of high duration assets (companies with high valuation or no earnings) and made financing more difficult.

With the type of drug discovery that might derive from AlphaFold and increased understanding of proteins will make biotechnology as massive and very profitable trend over the coming decades. Microsoft and the computer industry have generated 5-10% annualised alpha since the late 1980s and we believe biotechnology will ultimately do the same catapulting some of these companies into the top ranks of equity indices in terms of market value. One can invest in the stocks in our theme basket but requires decent amount of due diligence and it comes with the risks of not choosing the winners. An alternative is ETFs such as the iShares Nasdaq Biotechnology UCITS ETF (2B70:xetr) tracking the main benchmark index within biotechnology or the Global X Genomics & Biotechnology UCITS ETF (GNOM:xmil) which closer mimics our NextGen Medicine basket.

NameMkt Cap (USD mn.)Sales growth (%)R&D in % of mkt capDiff to PT (%)5yr return
Moderna Inc72,955227.63.36.1NA
BioNTech SE43,313831.02.433.9NA
Illumina Inc35,04934.03.735.014.7
Seagen Inc32,274-
Genmab A/S23,386-16.519.22.787.0
Argenx SE20,279-,930.3
Exact Sciences Corp8,42213.34.449.723.0
Grifols SA8,3360.14.358.4-38.5
Swedish Orphan Biovitrum AB6,75121.032.912.684.7
CRISPR Therapeutics AG6,08783,039.37.745.1327.1
Ionis Pharmaceuticals Inc5,81718.911.418.7-21.7
Intellia Therapeutics Inc5,439-
10X Genomics Inc4,80750.04.979.8NA
Natera Inc4,71848.56.563.1491.0
Arrowhead Pharmaceuticals Inc4,690195.65.772.82,310.9
Beam Therapeutics Inc4,428251,025.05.946.4NA
Denali Therapeutics Inc4,083-75.67.1105.9NA
Mirati Therapeutics Inc3,992495.313.361.71,395.4
Ultragenyx Pharmaceutical Inc3,754-7.014.2109.0-15.3
Abcam PLC3,57320.30.917.727.4
Galapagos NV3,4863.613.220.7-19.2
PTC Therapeutics Inc3,41132.316.04.3142.1
Fate Therapeutics Inc3,18342.28.7129.91,016.0
Twist Bioscience Corp2,58944.33.6-9.8NA
Sage Therapeutics Inc2,140-99.414.764.4-58.6
Allogene Therapeutics Inc1,956-99.511.598.2NA
Iovance Biotherapeutics Inc1,892NA14.9126.2115.0
CareDx Inc1,30439.46.3102.71,601.4
Pacific Biosciences of California Inc1,16931.914.8127.129.9
Invitae Corp45650.6101.7181.4-80.8
Aggregate / median323,73831.96.854.087.0
Source: Bloomberg and Saxo Group

Why is the protein folding problem so important?

In a recent podcast interview with Lex Friedman, Demis Hassabis (co-founder of DeepMind) describes why protein folding is such an important problem to solve. Proteins are the building blocks of life and our bodies and are responsible for most of what happens inside cells. Drugs for curing a disease attach to certain proteins and therefore you have to know their 3D shape to design the drug properly. With AlphaFold biologists can now look up the same of a protein in the database instead of using eight years on average, in some cases scientists have given up on finding certain protein structures, to determine the structure. It will turbocharge drug discovery and protein design.

The graphics below show how much better AlphaFold is relative to the competition in predicting protein structures with a score above 90 being on par with experimentally determined structures.


Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (
- Analysis Disclaimer (
- Notification on Non-Independent Investment Research (

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.